Moonjoo Han1, Anna L Roberts2, Brooke A Migliore3, Ana María Cárdenas3,4, Scott L Weiss2,5. 1. Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA. 2. Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Infectious Disease Diagnostics Laboratory, Children's Hospital of Philadelphia, Philadelphia, PA. 4. Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 5. Pediatric Sepsis Program, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Abstract
OBJECTIVES: Reactivation viremia is associated with adverse clinical outcomes and immune dysfunction in adults with sepsis. We determined the incidence of viremia and its association with clinical outcomes and immune paralysis phenotype in children with severe sepsis. DESIGN: Prospective cohort study. SETTING: Single academic PICU from September 2016 to March 2018. PATIENTS: Fifty-nine patients 2-17 years old treated for severe sepsis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We performed real-time polymerase chain reaction assays on whole blood specimens to determine the incidence of cytomegalovirus. Cytomegalovirus was detected in three patients (5%). All patients with cytomegalovirus viremia were seropositive, with an incidence of 13% in this subset. We additionally performed Epstein-Barr virus and human herpesvirus-6 polymerase chain reaction assays on last available specimens and detected Epstein-Barr virus in 4% and human herpesvirus-6 in 30% of the study population. Overall, viremia was not associated with clinical outcomes or immune function in univariable analyses. However, viremia was associated with lower odds of complicated course (defined as death within 28 d or ≥ 2 organ dysfunctions at 7 d) after controlling for age, Pediatric Risk of Mortality III score, and blood transfusion (adjusted odds ratio, 0.08; 95% CI, 0.01-0.84; p = 0.04). CONCLUSIONS: Children with severe sepsis had low rates of detectable viremia, which limited analyses of its association with clinical outcomes or immune paralysis phenotype. Given the rare occurrence of cytomegalovirus viremia, in particular, our study does not support a role for viremia as a biomarker of illness severity or as a modifiable risk factor of clinical outcomes for most patients. Future studies on the role of viremia in pediatric sepsis will need to consider the challenges posed by low rates of viremia in this population.
OBJECTIVES: Reactivation viremia is associated with adverse clinical outcomes and immune dysfunction in adults with sepsis. We determined the incidence of viremia and its association with clinical outcomes and immune paralysis phenotype in children with severe sepsis. DESIGN: Prospective cohort study. SETTING: Single academic PICU from September 2016 to March 2018. PATIENTS: Fifty-nine patients 2-17 years old treated for severe sepsis. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We performed real-time polymerase chain reaction assays on whole blood specimens to determine the incidence of cytomegalovirus. Cytomegalovirus was detected in three patients (5%). All patients with cytomegalovirus viremia were seropositive, with an incidence of 13% in this subset. We additionally performed Epstein-Barr virus and human herpesvirus-6 polymerase chain reaction assays on last available specimens and detected Epstein-Barr virus in 4% and human herpesvirus-6 in 30% of the study population. Overall, viremia was not associated with clinical outcomes or immune function in univariable analyses. However, viremia was associated with lower odds of complicated course (defined as death within 28 d or ≥ 2 organ dysfunctions at 7 d) after controlling for age, Pediatric Risk of Mortality III score, and blood transfusion (adjusted odds ratio, 0.08; 95% CI, 0.01-0.84; p = 0.04). CONCLUSIONS:Children with severe sepsis had low rates of detectable viremia, which limited analyses of its association with clinical outcomes or immune paralysis phenotype. Given the rare occurrence of cytomegalovirus viremia, in particular, our study does not support a role for viremia as a biomarker of illness severity or as a modifiable risk factor of clinical outcomes for most patients. Future studies on the role of viremia in pediatric sepsis will need to consider the challenges posed by low rates of viremia in this population.
Authors: Pavan Brahmamdam; Shigeaki Inoue; Jacqueline Unsinger; Katherine C Chang; Jonathan E McDunn; Richard S Hotchkiss Journal: J Leukoc Biol Date: 2010-05-18 Impact factor: 4.962
Authors: Scott L Weiss; Julie C Fitzgerald; John Pappachan; Derek Wheeler; Juan C Jaramillo-Bustamante; Asma Salloo; Sunit C Singhi; Simon Erickson; Jason A Roy; Jenny L Bush; Vinay M Nadkarni; Neal J Thomas Journal: Am J Respir Crit Care Med Date: 2015-05-15 Impact factor: 21.405
Authors: Sam Davila; E Scott Halstead; Mark W Hall; Allan Doctor; Russell Telford; Richard Holubkov; Joseph A Carcillo; Gregory A Storch Journal: Pediatr Crit Care Med Date: 2018-01 Impact factor: 3.624
Authors: Andrew H Walton; Jared T Muenzer; David Rasche; Jonathan S Boomer; Bryan Sato; Bernard H Brownstein; Alexandre Pachot; Terrence L Brooks; Elena Deych; William D Shannon; Jonathan M Green; Gregory A Storch; Richard S Hotchkiss Journal: PLoS One Date: 2014-06-11 Impact factor: 3.240
Authors: Azza Abd Elkader El Hamshary; Seham Awad El Sherbini; HebatAllah Fadel Elgebaly; Samah Abdelkrim Amin Journal: Rev Bras Ter Intensiva Date: 2017 Apr-Jun
Authors: Peter Ghazal; Patricia R S Rodrigues; Mallinath Chakraborty; Siva Oruganti; Thomas E Woolley Journal: EBioMedicine Date: 2022-05-03 Impact factor: 11.205